Cargando…

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes. The ALLG MDS4 phase II trial randomized such patients to standard azac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kenealy, Melita, Hertzberg, Mark, Benson, Warwick, Taylor, Kerry, Cunningham, Ilona, Stevenson, Will, Hiwase, Devendra, Eek, Richard, Zantomio, Daniela, Jong, Steve, Wall, Meaghan, Blombery, Piers, Gerber, Tracey, Debrincat, Marlyse, Zannino, Diana, Seymour, John F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442982/ https://www.ncbi.nlm.nih.gov/pubmed/30545923 http://dx.doi.org/10.3324/haematol.2018.201152

Ejemplares similares

Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide
por: Tiong, Ing S., et al.
Publicado: (2023)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
por: Žučenka, Andrius, et al.
Publicado: (2023)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
por: Mongiorgi, Sara, et al.
Publicado: (2023)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data
por: Sharplin, Kirsty, et al.
Publicado: (2023)

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
por: Rasmussen, Bengt, et al.
Publicado: (2022)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
por: McCormack, Steven E, et al.
Publicado: (2010)

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
por: Ritchie, Ellen K
Publicado: (2012)

Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations
por: Kim, Yoo-Jin, et al.
Publicado: (2013)

Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes
por: Kim, Kyuryung, et al.
Publicado: (2020)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
por: Sébert, Marie, et al.
Publicado: (2019)

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
por: Silverman, LR, et al.
Publicado: (2008)

Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines
por: Kutyna, Monika M., et al.
Publicado: (2023)

P737: LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL
por: Ross, David, et al.
Publicado: (2023)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
por: Valencia, A, et al.
Publicado: (2014)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome
por: Hashimoto, Miki, et al.
Publicado: (2019)

Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes
por: Yang, Yanli, et al.
Publicado: (2020)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Lenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case report
por: Garcia-Recio, Marta, et al.
Publicado: (2016)

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
por: Ebert, Benjamin L, et al.
Publicado: (2008)

DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
por: Tran, Huong Thi Thanh, et al.
Publicado: (2011)

A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine
por: Kumode, Takahiro, et al.
Publicado: (2014)

Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain
por: Crespo, Carlos, et al.
Publicado: (2013)

Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine
por: Daitoku, Shinya, et al.
Publicado: (2018)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
por: Stopka, Tomáš, et al.
Publicado: (2022)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Dry Dressing for Epidermal Sloughing after Subcutaneous Azacitidine Injection in a Myelodysplastic Syndrome
por: Lee, Jun Yong, et al.
Publicado: (2014)

An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum
por: Turan Erkek, Esra, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9f4t8mfppuedl6khsjk5l5d6us